A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia: With particular reference to drug resistance
- 31 January 1993
- journal article
- review article
- Published by Elsevier in Schizophrenia Research
- Vol. 8 (3) , 187-198
- https://doi.org/10.1016/0920-9964(93)90017-d
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Haloperidol decanoate in chronic schizophrenia: A study of 12 months with plasma levelsProgress in Neuro-Psychopharmacology and Biological Psychiatry, 1990
- Drug-Resistance Phenomena in Major Psychoses: Their Discrimination and Causal MechanismsClinical Neuropharmacology, 1990
- Dexamethasone suppression test in positive and negative schizophreniaPsychiatry Research, 1989
- Reduced Haloperidol/Haloperidol ratio and clinical outcome in schizophrenia: Preliminary evidencesProgress in Neuro-Psychopharmacology and Biological Psychiatry, 1988
- HALOPERIDOL METABOLISM AND ANTIPSYCHOTIC EFFECT IN SCHIZOPHRENIAThe Lancet, 1987
- Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms?American Journal of Psychiatry, 1986
- Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patientsPsychopharmacology, 1985
- Relationships Between Drug Concentrations in Serum and CSF, Clinical Effects and Monoaminergic Variables in Schizophrenic Patients Treated with Sulpiride or ChlorpromazineActa Psychiatrica Scandinavica, 1984
- Negative Symptoms in SchizophreniaArchives of General Psychiatry, 1982
- Animal model for investigation of fluphenazine kinetics after administration of long‐acting estersBiopharmaceutics & Drug Disposition, 1979